Grünenthal uses its own and third-party cookies to improve the browsing experience, offer personalized content and improve its services. We use analytics scripts which set tracking cookie, but we will activate these services only with your consent. If you press the button “Accept”, you consent to the use of these analytics scripts.

You can withdraw your consent at any time. To do so, please modify your configurations on this website by following this link to our privacy statement with the configuration options:
Go to settings



Supervisory Board

The Supervisory Board advises and controls the Corporate Executive Board and is elected by the shareholders’ summit. It approves the measures of the Corporate Executive Board in case these are subject to approval by corporate bylaws.

Prof. Dr. Wilhelm Moll LL.M.

Chairman of the Supervisory Board

Prof. Dr. Wilhelm Moll was born in Gevelsberg, Germany, on 31 October 1949. After gaining his certificate of secondary education, he served in the German Federal Border Guard. He then studied Law at universities in Marburg and Cologne, Germany, and then at the University of California, Berkeley, in the USA. He obtained his doctorate from the Faculty of Law at Cologne University, and the Master of Laws from Berkeley Law School. Since 2020, he has been an honorary professor at the University of Cologne.

Prof. Dr. Moll worked at the Institute for Labor and Business Law (Institut für Arbeits- und Wirtschaftsrecht) at Cologne University from 1975, first as research associate and last as assistant professor. He became a certified attorney at law in 1982. Prof. Dr. Moll is a partner of the law firm Heuking Kühn Lüer Wojtek. His main areas of expertise are employment/labor, and company law. His clients include big (DAX) and middle size enterprises. He provides comprehensive legal advice to medium-sized and owner-managed companies with regard to a multitude of problems and issues.

Apart from his legal consultancy and court-related activities, Prof. Dr. Moll also has a distinguished reputation through seminars and lectures, for instance lastly concerning questions about data protection in the employment relationship and the role of managing director in a GmbH (limited liability company). He is likewise the author of numerous legal publications, the last concerning commentaries on provisions of mass dismissals and of the German law regulating transformation of companies.

Hans-Reinhard Abels

Member of the Supervisory Board

Hans-Reinhard Abels was born on 5 November 1953 in Langenfeld, Germany. He holds a university degree in Communication and Educational Science. Additionally, he is a trained pilot and studied aeronautics in the USA.

Hans-Reinhard Abels gained a wealth of professional experience working for multiple well-known advertising agencies. He served as Managing Director for Publicis and as Managing Partner for Spiess Ermisch Abels, holding advisory mandates for international corporations and federal authorities. Hans-Reinhard Abels ended his advertising business career in 1992 and joined forces with the Grey Group. Together they founded Abels & Grey Mission Management Strategy Advisors. The company changed its name to Abels & Cie. in 2007 after dissolving the joint venture with the Grey Group.

Until 2008 Hans-Reinhard Abels served as a member of the Supervisory Board of the Berentzen Gruppe AG and was appointed member of Dalli’s Supervisory Board in 2008. He has been Chairman of Dalli’s Supervisory Board since 2014. He was active as author and guest lecturer, publishing numerous articles in specialist publications and business press.

Dr. Petra Danielsohn-Weil

Member of the Supervisory Board

Petra Danielsohn-Weil was born on February 15, 1960 in Herford, Germany. She studied Chemistry, Biology and Educational Psychology, and was awarded a PhD in Biology.

Petra Danielsohn-Weil has over 30 years of experience in the pharmaceutical industry. She spent a major part of her professional career in both strategic and operational roles at global, regional and local levels at Warner-Lambert and Pfizer.

Previously, she served in the Board of Directors of the “Association of Pharmaceutical Companies in Switzerland” (VIPS), the Advisory Board of the Frankfurter Allgemeine Zeitung Forum and the Board of Directors of the US-Russia Business Council. Currently, she serves as a Board Member and Independent Director at two corporations: NovaMedica and Invacare .

Petra Danielsohn-Weil is married and lives with her spouse in New York.

Dr. Gotthard Kleine

Member of the Supervisory Board

Dr. Gotthard Kleine was born on 24 June 1955 in Orsoy, Germany. He graduated in Physics and Theology and obtained his doctorate with honors from the Department of Mechanical Engineering of the RWTH Aachen. For his doctoral thesis he was awarded with the “Borchers Medal” of the RWTH Aachen University.

Throughout his career Dr. Kleine held numerous senior consulting positions and supported several companies in their strategic, organizational and personnel development as well as quality assurance. In 1995, he assumed a leadership role in industrial engineering at a research institute in Bremen alongside with a teaching assignment at the University of Bremen’s research division of production technology.

Since 2000 Gotthard Kleine has been Managing Director of an international child welfare organization and shareholder of the fair trade company GEPA. He is also member of the board of several foundations and member of the board of trustees of the Egidius-Braun-Stiftung of the German Soccer Federation (DFB). Additionally, he is member of the board of the Grünenthal Foundation and member of the Supervisory Board of a cooperative bank.

Dr. Martin Zügel

Member of the Supervisory Board

Dr. Martin Zügel was born on 6 April 1962. After studying medicine in Bochum and Tübingen and molecular biology (MSc) in Amherst, USA, he received his doctorate, Dr. med., in 1989.

Dr. Zügel has 30 years of experience in the healthcare sector, covering the full range of the industry. He draws on 20 years of board room experience in executive and non-executive positions, serving companies with global reach across Europe, Asia and the US.

After working in the hematology and oncology departments of the University Hospital Hamburg-Eppendorf (UKE), he switched to Boehringer Mannheim GmbH (later Hoffmann La Roche AG) in 1991 and joined B. Braun Melsungen AG as a Member of the Board in 2000. In 2005, he became part of the pharmaceutical company Merz as CEO of Merz Pharmaceuticals, and starting in 2008, he assumed the additional role of Spokesperson for Merz GmbH & Co. KGaA. Since his departure from Merz in 2012, Dr. Zügel has acted as Chairman of the Supervisory Board (Glycotope and Amsilk GmbH) and as a consultant for various companies in the pharmaceutical and biotech industry, and also as Senior Health Care Advisor for the private equity firm CVC Capital Partners. From 2015 to 2019, Dr. Zügel also served as Chief Executive Officer of Klosterfrau Zürich AG, a foundation-owned strategic holding that owns five companies in the healthcare and consumer sectors.